|
| |
Overview
Financial Highlight
HeadlinesBusiness Background Apex Healthcare Bhd is a public limited liability company, incorporated and domiciled in Malaysia. The Company is an investment holding company for a group of companies engaged in the business of manufacturing, marketing, distributing and retailing of pharmaceuticals, diagnostics, orthopaedics and consumer healthcare products with direct operations in Malaysia, Singapore and Vietnam. Its operations are organized into three segments: Manufacturing and Marketing, Wholesale and Distribution, and Corporate.
  moven00 The trend and behavior of AHealth for me resembles of Public Bank. Create value to shareholders in long term. 24/02/2023 2:50 PM troy88 wow, broke RM4 on uptrend. Too bad took profit a bit early 3.90. Apex stock has outperformed Kotra this year by a country mile.. 29/03/2023 9:58 AM Integrity. Intelligent. Industrious. 3iii (iiinvestsmart)$â¬Â£Â¥ Security LastPr PE DY% Divcts ROE ttm-marg AHEALTH (Pharmaceuticals) 4.09 19.35 2.1 8.5 17.92 11.5 30/03/2023 4:14 PM Nepo In the light of these results, the Board has proposed an increased final single-tier dividend of 3.5 sen per share as well as a special dividend of 2.0 sen per share in respect of financial year ended 31st December 2022 for shareholders’ approval at the forthcoming Annual General Meeting (‘AGM’) scheduled in May 2023. In all, total dividends paid and payable by the Group in respect of financial year 2022 is 8.5 sen per ordinary share, amounting to 40.2% of Group profit after tax. 27/04/2023 10:21 AM Nepo The Board is also proposing a 1 for 2 bonus issue of new shares, without capitalization of retained earnings, to reward shareholders for their continuous support and loyalty. We trust the bonus issue will help improve trading liquidity and enlarge our base of shareholders 27/04/2023 10:21 AM Nepo 2022 marks the 60th anniversary of the founding of the Group in 1962. From a retail pharmacy in Melaka, AHB has grown to a public company with a market capitalization of RM 1.68 billion1 with operations and commercial presence in 20 territories today. An initial investment in 1,000 shares at the time of AHB’s Initial Public Offering (‘IPO’) in year 2000 would be approximately 9,375 shares if held till today, after 4 bonus issues2 . At RM 1.50 per share at IPO, the value of that investment would be RM 33,000 today, based on the closing share price of RM 3.52 on 31st December 2022. This is a compound annual growth rate in value of 15.09% in each of the last 22 years and made possible through the support of every stakeholder, foremost our people, our customers, and our shareholders 27/04/2023 10:22 AM Nepo if this growth can persist, buy Ahealth let them runn our investment. At 15% compound interest is very good already not need hassle to buy what stocks to invest 27/04/2023 10:24 AM Nepo If you have choice, which way you would prefer: 1). Kill a goose and collect all the gold eggs one off worth around RM 350 million. If you put in FD @3.25%, you get RM 10 million interest. 2). You continue to rear the goose and collect aboutRM 30 million gold eggs every year with compound increment of around 10% additional eggs. You have the risk of goose being die off anytime though not possible in a foresable future 29/04/2023 10:15 PM wallstreetrookieNEW Healthcare is the only sector that will perform well alongside hard assets (gold/commodities) in an era of stagflation 05/05/2023 10:48 AM Nepo Cum dividend price RM 3.99 Dividend RM 0.06 Wondering ex dividend price can stabilise at how much? Today is 1 Jun 23 Happy Gawai 01/06/2023 8:20 AM Nepo Ahealth RM 3.93 TIMEDOTCOM RM 5.32 WCE RM 0.40 Padini RM 3.70 Pchem RM 6.52 Which counter has the best potential after 5 years? Anyone veteran can tell me..? Dated today 5 Jun 23 Five years later, which counters mentioned above has the best potential or best ROE? 05/06/2023 5:16 PM Nepo After Ex-Bonus, price stabilize at RM 2.60 which means any price below RM 2.50 is worth to top-up 08/06/2023 11:41 AM Nepo feeling pleasure today because no one comments here. I am the one who dominate this place it likes your are king in this place right now 08/06/2023 11:42 AM Nepo yes, i already topped up it is one of the counter in klse i long term buy in. i trust this mgt and hoping Dr Kee continues keep it upp.. 10/06/2023 9:38 AM Nepo waiting at RM 2.20 This is a money game. Only those have extra fund can survive..sigh.. 15/06/2023 9:37 AM Nepo The best time to collect this stock is when it is weak and now is the best chance to slowly accumulating this stock. 23/06/2023 11:50 AM moven00 Only way to buy AHealth is when there is blood all over here @ selldown with fundamental intact. Normal day can forget about it. 26/08/2023 9:27 AM moven00 Singapore Kia very kedekut one lo. Then we also have to remember there are sharks @ Fund Managers all waiting too. But in long term this singapore Kia create value to himself by giving bonus issue la. Retailer who hold long long indirectly benefited. That’s the characteristic of AHealth. Other than that don’t even think of them giving you generous dividend or Premium Buffet in AGM. Probably ask yourself to buy your own mineral water in their AGM. LOL 26/08/2023 9:34 AM Nepo Commentary a Prospects The Group’s core manufacturing and distribution businesses continue to perform well in the second quarter of 2023, driven by the Group’s commitment to sales growth, new product development, brand management, customer service and operational efficiency. Demand for pharmaceuticals, consumer healthcare products and medical devices remained firm in the first half of 2023, supported by the sales momentum from 2022. Business prospects for the Group’s Penang-based associate SAG remain unchanged from the first quarter. A portion of the proceeds received by SAG from the divestment of equity in SA to Quadria Capital has been paid to shareholders as dividends and the Group is actively evaluating opportunities to invest dividends received in new business projects. Details will be announced should these materialize. For the second half of 2023, the Group expects the business environment to be more challenging as economic growth in our key markets slows. However, the Group is confident that its proven and well-placed fundamentals, business development strategies, as well as new opportunities in consumer health, halal certification and international markets are expected to support performance. Barring any unforeseen circumstances, the Group expects to deliver a satisfactory result in 2023 and is confident that its longer-term growth prospects remain positive. 26/08/2023 10:12 AM Nepo （吉隆坡1日讯）Apex Healthcare Bhd建议以6650万令吉的价格，收购位于马六甲的工业用地。 该集团今日向大马交易所报备，独资子公司Xepa-Soul Pattinson（马）私人有限公司已与Panasonic Appliances Refrigeration Devices Malaysia私人有限公司（PAPRDMY）签署买卖协议。 “上述土地位置优越，与Xepa目前的生产基地坐落在同一工业区，距离仅400米。这提供了精益管理的优势，可最大限度减少重复的支援服务。” “此外，在这幅地的工业建筑经评估适合改造，以满足Xepa的制造要求，有效地降低新建成本。” Apex Healthcare表示：“这是及时的，因为Xepa目前正在评估扩大仓储和液体生产能力的计划。” 该集团指出，将通过内部资金和/或贷款来进行收购。 如无意外，收购计划将于2024年7月31日或之后完成。 截稿时，该股报2.41令吉，无起落，市值为17亿5000万令吉。 （编译：陈慧珊） English version：Apex Healthcare to acquire industrial land in Melaka for RM66.5 mil 01/12/2023 6:37 PM Nepo Apex Healthcare (Neutral, TP: RM2.41): Unit to acquire industrial complex in Melaka for RM66.5m. Apex Healthcare via its wholly-owned subsidiary Xepa-Soul Pattinson (M) SB has proposed to acquire an industrial property in Cheng Industrial Estate in Melaka from Panasonic Appliances Refrigeration Devices Malaysia SB for RM66.5m. (StarBiz) Comment: We view this strategic land acquisition positively as it aligns with XEPA’s plan to expand warehousing and liquid production capacity, positioning the company strategically for future growth. The acquisition will be funded through a combination of internally generated funds and possibly external borrowings. We gather that the property is located within the existing Cheng Industrial Estate in Melaka, in close proximity to XEPA, offering operational advantages by minimizing support service duplication. We maintain our earnings forecast and Neutral call on ApexH, as the acquisition is expected to only be finalised by the end of July 2024 with no near-term earnings contribution. 07/12/2023 1:37 PM wallstreetrookieNEW Disappointing earnings. Welp, Malaysia is lacking good healthcare/pharmaceutical players. This sector is so dead 05/03/2024 8:58 PM NoTimeToTrade Gone case, big fish all took their Dividend and Equity gains and left AHEALTH to go pump tech. Big trend TA says it will return to RM1.00. It was a good ride though. 17/05/2024 3:07 PM  | | ||||||||||||||||||||||||||||||||||||||||||||||||
